Hydroxychloroquine in SARS-CoV-2 infection: Understanding the misadventure

The widespread outbreak of SARS-CoV-2 was declared a public health emergency by the World Health Organization and various governments worldwide. This prompted the implementation of stringent infection control measures to curb the spread of the virus. Amidst this, the medical community faced the challenge of treating the virus without specific therapies or a vaccine, leading to reliance on empirical treatment approaches. In this context, hydroxychloroquine, an antimalarial and antirheumatic drug, gained attention as a potential treatment option. Despite its theoretical benefits, such as inhibiting viral entry, reducing inflammation, and modulating immune responses, empirical studies yielded inconsistent results. Some indicated a potential for symptom relief, while others showed no significant improvement in patient outcomes. The initial enthusiasm waned as the lack of substantial evidence led to revoking its Emergency Use Authorization, and several clinical trials were prematurely halted. The review in question critically examines the factors contributing to the ineffectiveness of hydroxychloroquine in treating SARS-CoV-2 infection, highlighting the complexities of drug repurposing during a rapidly evolving pandemic.

• Publication year

  2024

• Venue

  Journal of Acute Disease

• Publication date

  2024-04-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.4103/jad.jad_9_24
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Rethinking the role of hydroxychloroquine in the treatment of COVID‐19

  2020cited by this paper
• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

  2020cited by this paper
• Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment.

  2020cited by this paper
• Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

  2020cited by this paper
• Chloroquine and hydroxychloroquine as available weapons to fight COVID-19

  2020cited by this paper
• Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants

  2020cited by this paper
• In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

  2020cited by this paper
• Pharmacogenomics of COVID-19 therapies

  2020cited by this paper
• COVID-19: The Influence of ACE Genotype and ACE-I and ARBs on the Course of SARS-CoV-2 Infection in Elderly Patients

  2020cited by this paper
• Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

  2020cited by this paper
• Acute chloroquine and hydroxychloroquine toxicity: A review for emergency clinicians

  2020cited by this paper
• Effects of hydroxychloroquine treatment on QT interval

  2020cited by this paper
• Hydroxychloroquine inhibits trained immunity - implications for COVID-19

  2020cited by this paper
• A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

  2020cited by this paper
• Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

  2020cited by this paper
• Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data

  2020cited by this paper
• QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review

  2020cited by this paper
• Urgent need for evaluating agonists of angiotensin-(1-7)/Mas receptor axis for treating patients with COVID-19

  2020cited by this paper
• Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).

  2020cited by this paper
• Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

  2020cited by this paper
• National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 clinical management

  2020cited by this paper
• No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

  2020cited by this paper
• Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)

  2020cited by this paper
• Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis

  2019cited by this paper
• The Computerized ECG: Friend and Foe.

  2019cited by this paper
• Induction of Autonomous Memory Alveolar Macrophages Requires T Cell Help and Is Critical to Trained Immunity.

  2018cited by this paper
• Modulation of Myelopoiesis Progenitors Is an Integral Component of Trained Immunity

  2018cited by this paper
• Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: implications for biologics–small molecule drug interactions

  2017cited by this paper
• Expanding the B Cell-Centric View of Systemic Lupus Erythematosus.

  2017cited by this paper
• Trained immunity: A program of innate immune memory in health and disease

  2016cited by this paper
• Type I interferons in viral control and immune regulation

  2016cited by this paper
• Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes.

  2016cited by this paper
• Evaluation of disease‐mediated therapeutic protein–drug interactions between an anti–interleukin‐6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach

  2015cited by this paper
• Association of Polymorphisms of Cytochrome P450 2D6 With Blood Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus

  2015cited by this paper
• Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases

  2015cited by this paper
• Cardiac risks associated with antibiotics: azithromycin and levofloxacin

  2015cited by this paper
• Macrolide antibiotics and the risk of cardiac arrhythmias.

  2014cited by this paper
• Processing of human toll-like receptor 7 by furin-like proprotein convertases is required for its accumulation and activity in endosomes.

  2013cited by this paper
• Metabolism of inflammation limited by AMPK and pseudo-starvation

  2013cited by this paper
• Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

  2013cited by this paper
• Institution-wide QT alert system identifies patients with a high risk of mortality.

  2013cited by this paper
• The complex interplay between autophagy and NF-κB signaling pathways in cancer cells.

  2011cited by this paper
• Angiotensin II-Mediated Microvascular Thrombosis

  2010cited by this paper
• p65/RelA Modulates BECN1 Transcription and Autophagy

  2009cited by this paper
• Azithromycin‐Induced Torsade De Pointes

  2007cited by this paper
• Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century

  2007cited by this paper
• Potential antivirals and antiviral strategies against SARS coronavirus infections

  2006cited by this paper
• Antimicrobial-associated QT interval prolongation: pointes of interest.

  2006cited by this paper
• Binding interaction of SARS coronavirus 3CLpro protease with vacuolar‐H+ ATPase G1 subunit

  2005cited by this paper
• Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men

  2005cited by this paper
• Antibiotic Susceptibility of Tropheryma whipplei in MRC5 Cells

  2004cited by this paper
• Angiotensin II Induces Neutrophil Accumulation In Vivo Through Generation and Release of CXC Chemokines

  2004cited by this paper
• Antibiotics; adverse effects: Oral erythromycin and the risk of sudden death from cardiac causes

  2004cited by this paper
• Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy.

  2003cited by this paper
• Down‐regulation of human CYP3A4 by the inflammatory signal interleukin 6: molecular mechanism and transcription factors involved

  2002cited by this paper
• Mammalian ABC transporters in health and disease.

  2002cited by this paper
• Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.

  2002cited by this paper
• Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.

  2001cited by this paper
• Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis--a prospective, dose ranging study.

  2000cited by this paper
• Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties.

  2000cited by this paper
• Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR.

  2000cited by this paper
• Intracellular pH and the control of multidrug resistance.

  1994cited by this paper
• Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells.

  1988cited by this paper

• No citing papers are available for this paper.